KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Operating Income (2016 - 2025)

Travere Therapeutics' Operating Income history spans 13 years, with the latest figure at -$32.4 million for Q4 2025.

  • For Q4 2025, Operating Income rose 46.61% year-over-year to -$32.4 million; the TTM value through Dec 2025 reached -$62.8 million, up 80.6%, while the annual FY2025 figure was -$62.8 million, 80.6% up from the prior year.
  • Operating Income reached -$32.4 million in Q4 2025 per TVTX's latest filing, down from $24.9 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of $24.9 million in Q3 2025 to a low of -$139.2 million in Q1 2024.
  • Average Operating Income over 5 years is -$64.7 million, with a median of -$69.8 million recorded in 2022.
  • Peak YoY movement for Operating Income: tumbled 215.58% in 2021, then soared 144.4% in 2025.
  • A 5-year view of Operating Income shows it stood at -$84.8 million in 2021, then fell by 2.18% to -$86.7 million in 2022, then decreased by 8.69% to -$94.2 million in 2023, then surged by 35.55% to -$60.7 million in 2024, then surged by 46.61% to -$32.4 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Operating Income are -$32.4 million (Q4 2025), $24.9 million (Q3 2025), and -$12.6 million (Q2 2025).